Clinical Trial Update: Safety and Efficacy of ABX-101 in Participants Aged 18 to 50 Years of Age With Moderate to Severe Traumatic Brain Injury [Phase 2]

View source ↗

Summary

Phase 2 trial update on ABX-101 for moderate to severe traumatic brain injury and cerebral edema; efficacy and safety data are not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cerebral Edema
• Traumatic Brain Injury

Drugs mentioned

• ABX-101

Snippet

Sponsor: Abalonex, LLC | Conditions: Traumatic Brain Injury, Cerebral Edema | Phase 2 | Status: UNKNOWN